Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 7,245 matching trials from the live ClinicalTrials.gov search.

Filters: Detroit, Michigan Clear all

Conditions: Macular Edema Associated With Diabetes Mellitus
Interventions: Standard of Care, Macugen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Small-cell Lung Cancer
Interventions: ZL-1310, Investigator's Choice of Therapy; Drug
Lead sponsor: Zai Lab (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: La Jolla, California • Sacramento, California • Aurora, Colorado + 30 more

Conditions: Measles; Mumps; Rubella; Chickenpox, Measles
Interventions: Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more

Conditions: Vitiligo, Depigmented Scars, Depigmentation
Interventions: MKTP (melanocyte keratinocyte transplant procedure), Collagen Dressing, Vaseline Impregnated Gauze, Carbon Dioxide Laser, Dermabrasion; Procedure · Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Coronary Artery Disease (CAD)
Interventions: M118, Unfractionated Heparin; Drug
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 37
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 33 more

Conditions: Infertility
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 1,640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 12 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Nab paclitaxel, Gemcitabine, TheraBionic P1; Drug · Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Clarkston, Michigan • Detroit, Michigan • Flint, Michigan + 4 more

Conditions: Myocardial Ischemia, Coronary Arteriosclerosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency
Interventions: TP10; Drug
Lead sponsor: Avant Immunotherapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 18
States / cities: San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 15 more

Conditions: Cardiomyopathy, Pregnancy
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 16 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 28
States / cities: Los Angeles, California • Miami, Florida • Augusta, Georgia + 23 more

Conditions: Hypertension, Blood Pressure, Cardiovascular Disease Other
Interventions: PAL2; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer, Breast Neoplasms
Interventions: XL147 (SAR245408), trastuzumab, paclitaxel; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • Fort Meyers, Florida • Boston, Massachusetts + 4 more

Conditions: Acne Vulgaris
Interventions: IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 364 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 20
States / cities: Encino, California • Lake Mary, Florida • Miami, Florida + 15 more

Conditions: Ischemic Heart Failure
Interventions: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system; Device
Lead sponsor: BioCardia, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Clearwater, Florida • Atlanta, Georgia • Detroit, Michigan + 2 more

Conditions: Aortic Stenosis, Aortic Regurgitation, Aortic Valve Insufficiency, Heart Valve Diseases, Cardiovascular Abnormalities, Cardiovascular Diseases, Congenital Abnormalities, Heart Diseases, Pathological Conditions, Anatomical
Interventions: Mitroflow DL; Device
Lead sponsor: LivaNova; Industry
Eligibility: Not listed
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 9 more

Conditions: Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, B Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Peripheral T Cell Lymphoma
Interventions: BR101801 (Phase Ia), BR101801 (Phase Ib); Drug
Lead sponsor: Boryung Pharmaceutical Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Primary Membranous Nephropathy
Interventions: Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more

Conditions: Lymphoma, Low-Grade
Interventions: FavId (Id-KLH) active immunotherapy; Biological
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 8 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 51
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more

Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Interventions: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Abdominal Aortic Aneurysm
Interventions: TREO Abdominal Stent-Graft System; Device
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Teva Neuroscience, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 58
States / cities: Phoenix, Arizona • Sun City, Arizona • Fountain Valley, California + 51 more

Conditions: Covid19
Interventions: LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 98
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more

Conditions: Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 30 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 152
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more

Search by objective public record fields.

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Comparative Study Using Dermabrasion vs CO2 Laser & Collagen Dressing vs Vaseline Gauze in MKTP

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

Reproductive Medicine Network Biologic Specimen Repository

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery

Investigation in Pregnancy Associate Cardiomyopathy

Linkage, Empowerment, and Access to Prevent Hypertension

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction

Mitroflow DL Post Approval Study- North America

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Post-Approval Study of the TREO Abdominal Stent-Graft System

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

ACTIV-3: Therapeutics for Inpatients With COVID-19

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)